- Moody's•3 hours agoTakeda Pharmaceutical Company Limited -- Moody's confirms Takeda Pharmaceutical's A1 ratings; outlook negative
Tokyo, February 27, 2017-- Moody's Japan K.K. has confirmed the A1 issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. The rating outlook is negative. This rating action concludes ...
- PR Newswire•4 days agoTakeda and Cognition Kit partner in study to pilot wearable software in patients with Major Depressive Disorder (MDD)
CAMBRIDGE, England and DEERFIELD, Ill., Feb. 23, 2017 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited, a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Limited, announced a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD). Depression (MDD) is the leading cause of disability worldwide, affecting an estimated 350 million people of all ages.1 Cognitive problems are common in major depression and may be under recognized by both patients and clinicians.2,3 Cognitive testing provides the opportunity to detect and understand the pattern of cognitive symptoms in patients with MDD.
- PR Newswire•10 days agoFive-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
OSAKA, Japan, Feb. 17, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced that interim findings from the ongoing, open-label GEMINI long-term safety (LTS) study were presented during the 12th Congress of European Crohn's and Colitis Organisation (ECCO) in Barcelona, Spain, February 15-18, 2017. Data presented from two five-year interim analyses of effectiveness and safety in patients with moderate to severely active ulcerative colitis (UC) and Crohn's disease (CD) indicated that long-term treatment of vedolizumab in responders was associated with long-term clinical response and remission, in addition to health-related quality of life (HRQL) improvements for patients over a five-year period.
TKPYY : Summary for TAKEDA PHARMA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||23.71 - 23.81|
|52 Week Range||19.96 - 25.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.02|
|Dividend & Yield||0.78 (3.30%)|
|1y Target Est||N/A|